| Literature DB >> 35566008 |
Binh Thuc Tran1, Tuyen Ngoc Tran1, Ai My Thi Tran1, Giang Chau Dang Nguyen1, Quynh Trang Thi Nguyen2.
Abstract
In this paper, the classical least-squares (CLS) method with molecular absorption spectrophotometric measurement was used to determine simultaneously paracetamol (PAR), ibuprofen (IBU), and caffeine (CAF) in tablets. The absorbance spectra of the standard solutions and samples were measured over a wavelength from 220 to 300 nm with a 0.5 nm step. The concentration of PAR, IBU, and CAF in the sample solutions was calculated by using Visual Basic for Applications (VBA) and a program called CLS-Excel written in Microsoft Excel 2016. The method and the CLS-Excel program were tested on mixed standard laboratory samples with different PAR, IBU, and CAF concentration ratios, and they showed only small errors and a satisfying repeatability. An analytical procedure for tablets containing PAR, IBU, and CAF was developed. The reliability of the procedure was proved via the recovery and repeatability of the analysis results with an actual tablet sample and by comparing the mean contents of active substances in the tablets obtained from the analytical procedure with the HPLC method. The procedure is simple with a reduced cost compared with the HPLC standard method.Entities:
Keywords: caffeine; classical least-square; ibuprofen; paracetamol; simultaneous; spectroscopy
Mesh:
Substances:
Year: 2022 PMID: 35566008 PMCID: PMC9103904 DOI: 10.3390/molecules27092657
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Concentration of PAR, IBU, and CAF in the mixture, and their RE and statistics.
| Sample | Conc. Ratio (μg/mL) PAR/IBU/CAF | Run Order | PAR | IBU | CAF | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| RE (%) | Statistics | RE (%) | Statistics | RE (%) | Statistics | ||||||
| M1 | 16:12:7 | 1 | 16.091 | 0.57 | 11.858 | −1.18 | 6.989 | −0.16 | |||
| M2 | 14:10:6 | 1 | 13.992 | −0.06 | 10.004 | 0.04 | 5.991 | −0.15 | |||
| M3 | 12:8:5 | 1 | 11.943 | −0.47 | 8.023 | 0.29 | 4.957 | −0.86 | |||
| M4 | 10:6:4 | 1 | 9.979 | −0.21 | 6.040 | 0.67 | 3.961 | −0.98 | |||
| M5 | 8:4:3 | 1 | 7.899 | −1.26 | 4.023 | 0.58 | 2.971 | −0.97 | |||
| M6 | 6:2:2 | 1 | 5.973 | −0.45 | 1.998 | −0.10 | 2.003 | 0.15 | |||
| M7 | 4:10:1 | 1 | 4.009 | 0.23 | 10.053 | 0.53 | 1.006 | 0.60 | |||
| M8 | 15:10:1 | 1 | 14.929 | −0.47 | 9.984 | −0.16 | 1.008 | 0.80 | |||
| M9 | 8:5:0.5 | 1 | 8.004 | 0.05 | 4.974 | −0.52 | 0.507 | 1.40 | |||
Note: The number of decimal places is taken to represent the calculation result.
Figure 1UV absorption spectra of standard solutions and laboratory mixture solutions with different concentration ratios (Standard solution (µg/mL): PAR 10, IBU 10, CAF 5; PAR/IBU/CAF mixed solution (µg/mL): M1 (16:12:7); M2 (14:10:6); M3 (12:8:5); M4 (10:6:4); M5 (8:4:3); M6 (6:2:2); M7 (4:10:1); M8 (15:10:1; M9 (8:5:0.5)).
Figure 2Absorption spectra of standard solutions and sample solutions of ibuparavic (standard solution 10 µg/mL: PAR (1), IBU (2); standard solution 5 µg/mL: CAF (3); S1: Ibuparavic drug sample solution (4)).
Concentration of PAR, IBU, and CAF in sample solutions and their drug content in Ibuparavic tablets.
| Sample | PAR | IBU | CAF | |||
|---|---|---|---|---|---|---|
| Content | Content | Content | ||||
| S1 | 11.467 | 286.68 | 7.765 | 194.13 | 0.812 | 20.30 |
| S2 | 11.503 | 287.58 | 7.749 | 193.73 | 0.795 | 19.88 |
| S3 | 11.463 | 286.58 | 7.825 | 195.63 | 0.802 | 20.05 |
| Mean | 11.478 | 286.95 | 7.780 | 194.50 | 0.803 | 20.08 |
| RSD% | 0.192 | 0.515 | 1.052 | |||
| 1/2RSDH | 5.541 | 5.875 | 8.269 | |||
| %H* | 95.65 | 97.25 | 100.40 | |||
Note: %H*: % active ingredient compared with labelled content.
Figure 3Absorbance spectra of standard solutions, sample solution, and standard addition solutions (standard solution (µg/mL): PAR 10, IBU 10, CAF 5; S0: drug sample without standard S0 (m = 0.7 Mtablets); PAR/IBU/CAF mixed solution (µg/mL): S1 (2:2:0.5); S2 (4:4:1); S3 (6:6:1.5)).
Recovery of CLS-Excel method applied for analyzing Ibuparavic tablets.
| Repeated Sample | PAR | IBU | CAF | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Rev | Rev | Rev | |||||||
| S01 | 0 | 8.045 | 0 | 5.462 | – | 0 | 0.562 | ||
| S02 | 8.000 | – | 5.502 | 0.568 | – | ||||
| S03 | 7.987 | 5.483 | 0.564 | ||||||
| Statistics | |||||||||
| RSD% = 0.380 | RSD% = 0.360 | RSD% = 0.540 | |||||||
| S11 | 2.000 | 9.901 | 92.80 | 2.000 | 7.475 | 100.65 | 0.500 | 1.035 | 94.60 |
| S12 | 9.916 | 95.80 | 7.543 | 102.05 | 1.057 | 97.80 | |||
| S13 | 9.944 | 98.30 | 7.564 | 104.05 | 1.064 | 100.00 | |||
| Statistics | |||||||||
| RSD% = 0.22 | RSD% = 0.61 | RSD% = 1.44 | |||||||
| Revmean (%) = 95.63 | Revmean (%) = 102.25 | Revmean (%) = 97.47 | |||||||
| S21 | 4.000 | 11.824 | 94.48 | 4.000 | 9.551 | 102.23 | 1.000 | 1.578 | 101.60 |
| S22 | 11.713 | 92.83 | 9.538 | 100.90 | 1.585 | 101.70 | |||
| S23 | 11.711 | 93.10 | 9.536 | 101.33 | 1.582 | 101.80 | |||
| Statistics | |||||||||
| RSD% = 0.55 | RSD% = 0.09 | RSD% = 0.22 | |||||||
| Revmean (%) = 93.47 | Revmean (%) = 101.48 | Revmean (%) = 101.70 | |||||||
| S31 | 6.000 | 13.893 | 97.46 | 6.000 | 11.247 | 96.42 | 1.500 | 2.074 | 100.80 |
| S32 | 13.777 | 96.28 | 11.246 | 95.73 | 2.093 | 101.67 | |||
| S33 | 13.774 | 96.45 | 11.238 | 95.92 | 2.093 | 101.80 | |||
| Statistics | |||||||||
| RSD% = 0.49 | RSD% = 0.04 | RSD% = 0.52 | |||||||
| Revmean (%) = 96.73 | Revmean (%) = 96.02 | Revmean (%) = 101.42 | |||||||
Note: The number of decimal places is taken to represent the calculation result.
Comparison of CLS and HPLC methods.
| N0 | Content (H, mg/Tablet) | |||||
|---|---|---|---|---|---|---|
| PAR | IBU | CAF | ||||
| CLS | HPLC | CLS | HPLC | CLS | HPLC | |
| 1 | 286.68 | 287.98 | 194.13 | 193.02 | 20.30 | 20.37 |
| 2 | 287.58 | 285.26 | 193.73 | 195.90 | 19.88 | 20.19 |
| 3 | 286.58 | 289.18 | 195.63 | 195.69 | 20.05 | 19.98 |
|
| 286.95 | 287.47 | 194.50 | 194.87 | 20.08 | 20.18 |
| RSD (%) | 0.19 | 0.73 | 0.51 | 0.83 | 1.05 | 0.99 |
|
| 0.438 | 0.342 | 0.622 | |||
| 2.78 | 2.78 | 2.78 | ||||
|
| 0.68 | 0.75 | 0.57 | |||